High-frequency repetitive transcranial magnetic stimulation combined with cognitive training improves cognitive function and cortical metabolic ratios in Alzheimer’s disease

Zhang, Fengxia; Qin, Yuanyuan; Xie, Lingfeng; Zheng, Caixia; Huang, Xiaolin; Zhang, Min

doi:10.1007/s00702-019-02022-y

Cited by 57 publications

(115 citation statements)

References 50 publications

Supporting

Mentioning

109

Contrasting

Order By: Relevance

“…According to previous studies, the left DLPFC may be an effective target for patients with AD [26,50,51]. Therefore, we restricted our target within the left DLPFC, a sphere region centered on Montreal Neurological Institute (MNI) coordinates [À38 44 26] [52] with a 10-mm radius.…”

Section: Study Interventions: Mri-navigated Rtmsmentioning

confidence: 99%

Accelerated intermittent theta-burst stimulation broadly ameliorates symptoms and cognition in Alzheimer's disease: A randomized controlled trial

Geng

et al. 2022

Brain Stimulation

View full text Add to dashboard Cite

Section: Study Interventions: Mri-navigated Rtmsmentioning

confidence: 99%

Accelerated intermittent theta-burst stimulation broadly ameliorates symptoms and cognition in Alzheimer's disease: A randomized controlled trial

Geng

et al. 2022

Brain Stimulation

View full text Add to dashboard Cite

“…Mild to moderate AD patients undergoing cognitive training received real or sham rTMS treatment for 4 weeks. Compared to the sham group, the treated group showed better performance in general cognitive and behavioral functions [ 115 ]. Stimulation at the left DLPFC seems to be the most popular and promising protocol in AD treatment.…”

Section: Novel Therapeutic Approachmentioning

confidence: 99%

“…A recent meta-analysis concluded that both high-frequency and low-frequency rTMS resulted in cognitive improvement in AD patients, with medium to large effect sizes [ 270 ]. The after effect of five or more sessions of rTMS could last from a few weeks to 4 months [ 114 , 115 , 116 , 117 , 118 , 270 , 271 ].…”

Section: Novel Therapeutic Approachmentioning

confidence: 99%

Novel Therapeutic Approaches for Alzheimer’s Disease: An Updated Review

Lane

Lin

2021

IJMS

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a progressive neurodegenerative disease and accounts for most cases of dementia. The prevalence of AD has increased in the current rapidly aging society and contributes to a heavy burden on families and society. Despite the profound impact of AD, current treatments are unable to achieve satisfactory therapeutic effects or stop the progression of the disease. Finding novel treatments for AD has become urgent. In this paper, we reviewed novel therapeutic approaches in five categories: anti-amyloid therapy, anti-tau therapy, anti-neuroinflammatory therapy, neuroprotective agents including N-methyl-D-aspartate (NMDA) receptor modulators, and brain stimulation. The trend of therapeutic development is shifting from a single pathological target to a more complex mechanism, such as the neuroinflammatory and neurodegenerative processes. While drug repositioning may accelerate pharmacological development, non-pharmacological interventions, especially repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS), also have the potential for clinical application. In the future, it is possible for physicians to choose appropriate interventions individually on the basis of precision medicine.

show abstract

“…In recent years, repetitive transcranial magnetic stimulation (rTMS) therapy has been considered to be a promising treatment protocol for psychiatric and neurological disorders [2][3][4], including mild cognitive impairment (MCI) and Alzheimer's disease [5][6][7][8]. Previous studies have demonstrated that rTMS improves language performance [9][10][11], attentional capacity [12], executive function [13][14][15], verbal memory and episodic memory [16][17][18][19]. Despite its therapeutic effectiveness, there is no consensus on the most effective target region for clinical treatment of Alzheimer's disease with rTMS, with varying spatial regions in different studies, including dorsolateral prefrontal cortex (DLPFC) [9,20], inferior frontal gyrus [12,13], precuneus [21], and posterior temporal gyrus [16].…”

Section: Introductionmentioning

confidence: 99%

Cognitive Improvement is Correlated with Increased Dynamic Functional Connectivity of Default Mode Network by Personalized rTMS in Alzheimer's Disease

Wei¹,

Wang²,

Zhang³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Repetitive transcranial magnetic stimulation (rTMS) is thought to be a promising therapeutic approach for Alzheimer's disease patients. Methods In the present report, a double-blind, randomized, sham-controlled rTMS trial was conducted in mild-to-moderate Alzheimer's disease patients. High-frequency rTMS was delivered to a subject-specific left lateral parietal region that demonstrated highest functional connectivity with the hippocampus using resting-state fMRI. The Mini Mental State Examination (MMSE) and Philadelphia Verbal Learning Test (PVLT) were used to evaluate patients’ cognitive functions. Results Patients receiving active rTMS treatment (n = 31) showed a significant increase in the MMSE, PVLT-Immediate recall, and PVLT-Short Delay recall scores after two weeks of rTMS treatment, whereas patients who received sham rTMS (n = 27) did not show significant changes in these measures. Dynamic functional connectivity (dFC) magnitude of the default mode network (DMN) in the active-rTMS group showed a significant increase after two weeks of rTMS treatment, and no significant changes were found in the sham-rTMS group. There was a significantly positive correlation between changes of the MMSE and changes of the dFC magnitude of DMN in the active-rTMS group, but not the sham-rTMS group. Conclusions Our findings are novel in demonstrating the feasibility and effectiveness of the fMRI-guided rTMS treatment in Alzheimer's disease patients, and DMN might play a vital role in therapeutic effectiveness of rTMS in Alzheimer’s disease. Trial registration: China National Medical Research Platform (http://114.255.48.20/login, No:MR-33-20-004217), retrospectively registered 2020-12-23.

show abstract

High-frequency repetitive transcranial magnetic stimulation combined with cognitive training improves cognitive function and cortical metabolic ratios in Alzheimer’s disease

Cited by 57 publications

References 50 publications

Accelerated intermittent theta-burst stimulation broadly ameliorates symptoms and cognition in Alzheimer's disease: A randomized controlled trial

Accelerated intermittent theta-burst stimulation broadly ameliorates symptoms and cognition in Alzheimer's disease: A randomized controlled trial

Novel Therapeutic Approaches for Alzheimer’s Disease: An Updated Review

Cognitive Improvement is Correlated with Increased Dynamic Functional Connectivity of Default Mode Network by Personalized rTMS in Alzheimer's Disease

Contact Info

Product

Resources

About